EXHIBIT 10.47
================================================================================
This Warrant and the Common Stock issuable upon exercise hereof have not been
registered or qualified under the Securities Act of 1933, as amended, or any
state securities laws, and may not be sold or transferred unless Registered or
qualified pursuant to such Act and applicable state securities laws or an
exemption therefrom under said Act or any such state securities laws is
available.
This Warrant and the Common Stock issuable upon exercise hereof are subject to
certain restrictions on transfer and certain rights specified in the Securities
Agreement dated as of November 24, 1999, as amended from time to time, among
Nexell Therapeutics Inc., the original Holder of this Warrant and the other
parties that are signatories thereto, a copy of which will be mailed to any
requesting Holder within five (5) days of written request therefor.
No. AWR-___ Adjusted Number of Shares
Class A Warrant to Purchase
Shares of Common Stock
of
Nexell Therapeutics Inc.
================================================================================
Table of Contents
Section Heading Page
Section 1. Exercise of Warrant................................................................ 1
Section 2. Reservation........................................................................ 2
Section 3. Protection Against Dilution........................................................ 3
Section 3.1. Stock Dividends, Subdivisions and Combinations..................................... 3
Section 3.2. Issuance of Additional Shares of Common Stock...................................... 3
Section 3.3. Issuance of Warrants or Other Rights, Convertible Securities....................... 4
Section 3.4. Other Provisions Applicable to Adjustments......................................... 4
Section 3.5. Extraordinary Dividends............................................................ 6
Section 3.6. Additional Adjustments, etc........................................................ 6
Section 3.7. Adjustment of Number of Shares Purchasable......................................... 7
Section 3.8. Minimum Adjustment................................................................. 7
Section 3.9. Notice of Adjustments.............................................................. 7
Section 4. Mergers, Consolidations, Sales Reorganizations or Reclassification................. 8
Section 5. Dissolution or Liquidation......................................................... 9
Section 6. Notice of Extraordinary Dividends.................................................. 9
Section 7. Fractional Shares.................................................................. 9
Section 8. Fully Paid Stock; Taxes............................................................ 10
Section 9. Restrictions on Transferability.................................................... 10
Section 9.1. In General......................................................................... 10
Section 9.2. Restrictive Legends................................................................ 10
Section 9.3. Transfers to Competitors........................................................... 11
Section 9.4. Transfers with Related Securities.................................................. 11
Section 9.5. Minimum Transfers.................................................................. 11
Section 10. Partial Exercise and Partial Assignment............................................ 11
Section 10.1. Partial Exercise................................................................... 11
Section 10.2. Assignment......................................................................... 00
-x-
Xxxxxxx 00. Preemption......................................................................... 12
Section 12. Warrant Denominations.............................................................. 12
Section 13. Definitions........................................................................ 12
Section 14. Lost, Stolen Warrants, Etc......................................................... 17
Section 15. Warrant Holder Not Shareholder..................................................... 17
Section 16. Exercise of Remedies............................................................... 18
Section 17. Notices............................................................................ 18
Section 18. Severability....................................................................... 18
Section 19. Register; Closing of Transfer Books................................................ 19
Section 20. Financial Statements; Notice of Exercise Period.................................... 19
Section 21. [Intentionally Omitted]............................................................ 19
Section 22. Restrictions on Capital Structure.................................................. 19
Section 23. Successors and Assigns............................................................. 20
Section 24. Index and Captions................................................................. 20
Section 25. Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.................... 20
Signature.............................................................................................. 22
-ii-
No. AWR-____ Adjusted Number of Shares
Class A Warrant to Purchase
Shares of Common Stock
of
Nexell Therapeutics Inc.
This is to Certify that, for value received and subject to the provisions
hereinafter set forth,
[Purchaser]
or assigns,
is entitled to purchase from Nexell Therapeutics Inc., a Delaware corporation
(the "Company"), at any time during the Exercise Period, the Adjusted Number of
Shares (as hereinafter defined) of Common Stock, $.001 par value, of the
Company, subject to the terms, provisions and conditions hereinafter set forth
at a price equal to $.01 per share.
The aggregate price of the Common Stock shall be equal to the price per
share multiplied by the Adjusted Number of Shares which would be purchasable
hereunder at the Initial Exercise Time if no adjustment described in Section 3
were made. The aggregate price is herein sometimes referred to as the "Aggregate
Warrant Price" and is not subject to adjustment. The price per share is,
however, subject to adjustment as hereinafter provided (such price, or such
price as last adjusted, as the case may be, being herein referred to as the "per
share Warrant Price"). The Adjusted Number of Shares purchasable hereunder is
likewise subject to adjustment as hereinafter provided.
The terms which are capitalized herein shall have the meanings specified in
Section 13 hereof, unless the context shall otherwise require.
Section 1. Exercise of Warrant.
Subject to the conditions hereinafter set forth, this Warrant may be
exercised in whole or in part at any time during the Exercise Period. Any
exercise of this Warrant, whether in whole or in part, shall be made by the
surrender of this Warrant (with the subscription form at the end hereof duly
completed and executed) at the principal office of the Company in Irvine,
California and upon payment of the Aggregate Warrant Price (or, if exercised in
part, upon payment of a proportionate part thereof) for the shares so purchased,
which payment shall be made by the wire transfer or other delivery to the
Company of one or more types of Permitted Consideration.
In the event that Preferred Stock shall be delivered to the Company as
payment of all or any portion of the Warrant Price, the amount of the Warrant
Price to be paid by means of such delivery shall equal the aggregate of the then
applicable liquidation preference of the shares of Preferred Stock so delivered
(based on an initial liquidation preference of $1,000.00 per share) or such
lesser amount of such liquidation preference as shall be designated by the
Holder hereof.
In the event that Preferred Stock shall be delivered to the Company as
payment of all or any portion of the Warrant Price and the aggregate liquidation
preference of such shares shall be in excess of the amount of per share
liquidation preference sought to be applied by the Holder of this Warrant in
respect of the Warrant Price, said Holder shall provide the Company with notice
to such effect and the Company shall (without charge to the Holder) issue to
said Holder a new Preferred Stock certificate for the number of shares with an
aggregate per share liquidation preference equal to such excess as provided in
Section 5.05 of the Securities Agreement.
In the event that Warrants shall be delivered to the Company as payment of
all or any portion of the Warrant Price, the amount of the Warrant Price deemed
to be paid by means of such delivery shall equal (a) the aggregate number of
Underlying Shares related to any Warrants so delivered, multiplied by (b) the
per share Warrant Price then in effect.
If this Warrant is exercised in respect of less than all of the shares of
Common Stock at the time purchasable hereunder, the Holder hereof shall be
entitled to receive a new Warrant covering the number of shares in respect of
which this Warrant shall not have been exercised and setting forth the Aggregate
Warrant Price applicable to such shares.
This Warrant and all rights and options hereunder shall expire at the
earlier of (a) 5:00 p.m. (New York, New York time) on the Expiration Date or (b)
the exercise by the Holder of the Put Right Certificates issued by Xxxxxx
International Inc., a Delaware corporation, to such Holder concurrently with,
and as part of an investment unit including, this Warrant and certain Series B
Preferred Stock, and shall be wholly null and void to the extent this Warrant is
not exercised before such expiration.
The Company shall pay all reasonable expenses, taxes and other charges
payable in connection with the preparation, execution and delivery of stock
certificates pursuant to this Section, regardless of the name or names in which
such stock certificates shall be registered.
Section 2. Reservation.
The Company will at all times prior to the Expiration Date reserve and keep
available such number of authorized shares of its Common Stock, solely for the
purpose of delivery upon the exercise of the rights represented by this Warrant,
as may at such time be deliverable (based upon the number of shares of Common
Stock outstanding at any such time) upon the exercise of this Warrant and such
shares issuable upon the exercise of this Warrant shall at no time have an
aggregate par value which is in excess of the Aggregate Warrant Price.
-2-
Section 3. Protection Against Dilution.
The per share Warrant Price and the number of shares deliverable hereunder
shall be adjusted from time to time as hereinafter set forth:
Section 3.1. Stock Dividends, Subdivisions and Combinations. In case
after the date hereof the Company shall:
(a) take a record of the Holders of its Common Stock for the
purpose of entitling them to receive a dividend and declared to be payable
in, or other declared distribution of, Common Stock, or
(b) subdivide its outstanding shares of Common Stock into a
larger number of shares of Common Stock, or
(c) combine its outstanding shares of Common Stock into a
smaller number of shares of Common Stock,
then the per share Warrant Price shall be adjusted to that price determined by
multiplying the per share Warrant Price in effect immediately prior to such
event by a fraction (i) the numerator of which shall be the total number of
outstanding shares of Common Stock of the Company immediately prior to such
event, and (ii) the denominator of which shall be the total number of
outstanding shares of Common Stock of the Company immediately after such event.
Section 3.2. Issuance of Additional Shares of Common Stock. In case
after the date hereof the Company shall (except as hereinafter provided) issue
any Additional Shares of Common Stock for a consideration per share less than
the then effective per share Warrant Price, then the per share Warrant Price
upon each such issuance shall be adjusted to that price determined by
multiplying the per share Warrant Price in effect immediately prior to such
event by a fraction:
(a) the numerator of which shall be the number of shares of
Common Stock outstanding immediately prior to the issuance of such
Additional Shares of Common Stock plus the number of full shares of Common
Stock which the aggregate consideration for the total number of such
Additional Shares of Common Stock so issued would purchase at the then
effective per share Warrant Price, and
(b) the denominator of which shall be the number of shares of
Common Stock outstanding immediately prior to the issuance of such
Additional Shares of Common Stock plus the number of such Additional Shares
of Common Stock so issued.
The provisions of this Section 3.2 shall not apply to any Additional Shares
of Common Stock which are distributed to holders of Common Stock as a stock
dividend or subdivision, for which an adjustment is provided for under
Section 3.1. No adjustment of the per share Warrant Price shall be made under
this Section 3.2 upon the issuance of any Additional Shares of Common Stock
which are issued pursuant to the exercise of any warrants or other subscription
or
-3-
purchase rights or pursuant to the exercise of any conversion or exchange rights
in any Convertible Securities, if any such adjustment shall previously have been
made upon the issuance of such warrants or other rights or upon the issuance of
such Convertible Securities (or upon the issuance of any warrants or other
rights therefor) pursuant to Section 3.3.
Section 3.3. Issuance of Warrants or Other Rights, Convertible
Securities. In case the Company shall issue any warrants or other rights to
subscribe for or purchase any Additional Shares of Common Stock or issue
Convertible Securities (other than Series A Preferred Stock issued as a dividend
on the Series A Preferred Stock in accordance with the Company's Certificate of
Incorporation) and the consideration per share for which Additional Shares of
Common Stock may at any time thereafter be issuable pursuant to such warrants or
other rights or pursuant to the terms of such Convertible Securities shall be
less than the effective per share Warrant Price, then the per share Warrant
Price shall be adjusted as provided in Section 3.2 above on the basis that:
(a) the maximum number of Additional Shares of Common Stock
issuable pursuant to all such warrants or other rights or necessary to
effect the conversion or exchange of all such Convertible Securities shall
be deemed to have been issued as of the earlier of: (i) the date on which
the Company shall enter a firm contract or commitment for the issuance of
such warrants, other rights or Convertible Securities or (ii) the date of
actual issuance of such warrants, other rights or Convertible Securities,
and
(b) the aggregate consideration for such maximum number of
Additional Shares of Common Stock shall be deemed to be the minimum
consideration received and receivable by the Company for the issuance of
such Additional Shares of Common Stock pursuant to such warrants or other
rights or pursuant to the terms of such Convertible Securities.
No adjustment of the per share Warrant Price shall be made under this
Section 3.3 upon the issuance of any Convertible Securities which are issued
pursuant to the exercise of any warrants or other subscription or purchase
rights therefor, to the extent such adjustment shall previously have been made
upon the issuance of such warrants or other rights pursuant to this Section 3.3.
Section 3.4. Other Provisions Applicable to Adjustments. The following
provisions shall be applicable to the making of adjustments in the per share
Warrant Price hereinbefore provided in this Section 3:
(a) Computation of Consideration. To the extent that any
Additional Shares of Common Stock or any Convertible Securities or any
options, warrants or other rights to subscribe for or purchase any
Additional Shares of Common Stock or any Convertible Securities shall be
issued for a cash consideration, the consideration received by the Company
therefor shall be deemed to be the amount of the cash received by the
Company therefor, or, if such Additional Shares of Common Stock or
Convertible Securities or options, warrants or other rights are offered by
the Company for subscription, the subscription price, or, if such
Additional Shares of Common Stock or Convertible
-4-
Securities or options, warrants or other rights are sold to underwriters or
dealers for public offering without a subscription offering, the initial
offering price, in any such case excluding any amounts paid or receivable
for accrued interest or accrued dividends and without deduction of any
compensation, discounts or expenses paid or incurred by the Company for and
in the underwriting thereof, or otherwise in connection with the issue
thereof. To the extent that such issuance shall be for a consideration
other than cash, then, except as herein otherwise expressly provided, the
amount of such consideration shall be deemed to be the fair value of such
consideration at the time of such issuance as determined in good faith by
the Board of Directors of the Company. The consideration for any Additional
Shares of Common Stock issuable pursuant to any options, warrants or other
rights to subscribe for or purchase the same shall be the consideration
received by the Company for issuing such options, warrants or other rights
plus the additional consideration payable to the Company upon the exercise
of such options, warrants or other rights. The consideration for any
Additional Shares of Common Stock issuable pursuant to the terms of any
Convertible Securities shall be the consideration received by the Company
for issuing any options, warrants or other rights to subscribe for or
purchase such Convertible Securities plus the consideration paid or payable
to the Company in respect of the subscription for or purchase of such
Convertible Securities plus the additional consideration, if any, payable
to the Company upon the exercise of the right of conversion or exchange of
such Convertible Securities. In case of the issuance at any time of any
Additional Shares of Common Stock or Convertible Securities in payment or
satisfaction of any dividend upon any class of equity securities other than
Common Stock, the Company shall be deemed to have received for such
Additional Shares of Common Stock or Convertible Securities a consideration
equal to the amount of such dividend so paid or satisfied.
(b) Readjustment of Per Share Warrant Price. Upon expiration of the
right of exercise, conversion or exchange of any Convertible Securities, or
upon the expiration of any rights, options or warrants, or upon the
termination of any firm contract or commitment for the issuance of such
rights, options, warrants or Convertible Securities, or upon any increase
in the minimum consideration receivable by the Company for the issuance of
Additional Shares of Common Stock pursuant to such Convertible Securities,
rights, options or warrants, if any such Convertible Securities shall not
have been converted or exchanged, or if any such rights, options or
warrants shall not have been exercised, the number of shares of Common
Stock deemed to be issued and outstanding by reason of the fact that they
were issuable upon conversion or exchange of any such Convertible
Securities or upon exercise of any such rights, options or warrants shall
no longer be computed as set forth above, and the per share Warrant Price
shall forthwith be readjusted and thereafter be the price which it would
have been (but reflecting any other adjustments in the per share Warrant
Price made pursuant to the provisions of this Section 3 after the issuance
of such Convertible Securities, rights, options or warrants) had the
adjustment of the per share Warrant Price made upon the issuance or sale of
such Convertible Securities or the issuance of such rights, options or
warrants been made on the basis of the issuance only of the number of
Additional Shares of Common Stock actually issued upon conversion or
exchange of such Convertible Securities or upon the exercise of such
rights, options or warrants, or upon the basis of such increased minimum
-5-
consideration, as the case may be, and thereupon only the number of
Additional Shares of Common Stock actually so issued plus the number
thereof then issuable upon the basis of such increased minimum
consideration shall be deemed to have been issued and only the
consideration actually received plus such increased minimum consideration
receivable by the Company (computed in accordance with Section 3.4(a))
shall be deemed to have been received by the Company.
(c) No Rounding Per Share Warrant Price. Any determination of per
share Warrant Price hereunder shall be expressed in United States Dollars,
cents and portions of cents and shall not be subject to rounding.
Section 3.5. Extraordinary Dividends. In case the Company shall declare
a dividend upon its Common Stock (except a dividend payable in shares of Common
Stock referred to in Section 3.1(a) or a dividend payable in warrants, rights or
Convertible Securities referred to in Section 3.3) payable otherwise than out of
earnings or surplus (other than revaluation surplus or paid-in surplus), the per
share Warrant Price in effect immediately prior to the declaration of such
dividend shall be reduced by an amount equal, in the case of a dividend in cash,
to the amount thereof payable per share of Common Stock or, in the case of any
other dividend, to the fair value thereof per share of Common Stock as
determined in good faith by the Board of Directors of the Company. For the
purposes of the foregoing, a dividend payable other than in cash shall be
considered payable out of earnings or surplus (other than revaluation surplus or
paid-in surplus) only to the extent that such earnings or surplus are charged an
amount equal to the fair value of such dividend as determined by the Board of
Directors of the Company. If such dividend is paid or the Company declares and
becomes legally liable to pay such dividend, such reduction shall take effect as
of the date on which a record is taken for the purpose of such dividend or, if a
record is not taken, the date as of which the Holders of the Common Stock of
record entitled to such dividend are to be determined. Appropriate readjustment
of the per share Warrant Price shall be made in the event that any dividend
referred to in this Section 3.5 shall be lawfully abandoned.
Section 3.6. Additional Adjustments, etc. If any other transaction or
event shall occur (excluding any transaction or event explicitly referred to in
this Section 3, but including, without limitation, any issuance repurchase,
redemption, or other distribution in respect of any shares or capital stock or
other securities of the Company or of any other person) as to which the other
provisions of this Section 3 are not strictly applicable but the failure to make
any adjustment to the per share Warrant Price would not fairly protect the
exercise rights and other rights of the Holder of this Warrant, then, and as a
condition to the consummation of any such transaction or event, and in each such
case, the Board of Directors shall promptly determine the adjustment, if any, on
a basis consistent with the essential intent and principles established in this
Section 3, which is necessary to preserve, without dilution, the exercise rights
of this Warrant and, promptly following such determination, the Company shall
furnish to each Holder of the Warrants a certificate setting forth such
adjustment and showing in detail the facts upon which such adjustment is based.
The adjustment set forth in such certificate shall be binding upon the Company
and the Holders of the Warrants unless, within 30 days following receipt of such
certificate, the Holders of 20% or more of the outstanding Warrants (determined
by the number of shares of Common Stock represented by each such Warrant if
exercised) shall notify the
-6-
Company of their disagreement with such adjustment, in which event such
adjustment shall be determined at the expense of the Company by its independent
auditors (so long as such auditors' accounting firm ranks among the five largest
national accounting firms) or by an independent investment banking firm or other
professional of recognized national standing selected by the Company and, in all
such cases (including the Company's selection of its auditors), reasonably
satisfactory to the Required Holders, which shall give its opinion as to the
adjustment, if any, on a basis consistent with the essential intent and
principles established in this Section 3, which is necessary to preserve,
without dilution, the exercise rights of each Warrant. The opinion of any such
auditor, banking firm or other professional shall be conclusive evidence of the
correctness of any computation made under this Section 3. The Company shall pay
all fees and expenses in connection with any such opinion. Upon receipt of such
opinion, the Company will promptly deliver a copy thereof to each Holder of any
Warrant and the Company shall (subject to obtaining necessary director and
stockholder actions), take all actions necessary or appropriate under the laws
of the State of Delaware and the Certificate of Incorporation consistent with
such opinion to effect the intent and principles hereof.
Section 3.7. Adjustment of Number of Shares Purchasable. Upon each
adjustment of the per share Warrant Price, the Adjusted Number of Shares of
Common Stock (for each level of Adjusted Number of Shares corresponding to the
ranges of "Current Market Price on the First Day of the Exercise Period" as set
forth in the definition thereof) purchasable hereunder shall be adjusted by
multiplying the Adjusted Number of Shares of Common Stock (in each such level)
which would have been purchasable hereunder if there had been no such adjustment
of the per share Warrant Price (though taking into account all prior adjustments
of the per share Warrant Price) by a fraction, the numerator of which shall be
the per share Warrant Price in effect immediately prior to such adjustment and
the denominator of which shall be the per share Warrant Price in effect
immediately following such adjustment.
Section 3.8. Minimum Adjustment. Except as hereinafter provided, no
adjustment of the per share Warrant Price hereunder shall be made if such
adjustment results in a change of the per share Warrant Price then in effect of
less than 0.001%. Any adjustment of less than 0.001% shall be carried forward
and shall be made at the time of and together with any subsequent adjustment
which, together with the adjustment or adjustments so carried forward, amounts
to 0.001% or more of the per share Warrant Price then in effect. However, upon
the exercise of this Warrant, the Company shall make all necessary adjustments
not theretofore made to the per share Warrant Price up to and including the date
upon which this Warrant is exercised.
Section 3.9. Notice of Adjustments. (a) Whenever the per share Warrant
Price or number of shares deliverable upon exercise of this Warrant shall be
adjusted pursuant to this Section 3, the Company at is expense shall promptly
prepare a certificate signed by the Chief Financial Officer or the Chief
Operating Officer and by the Treasurer or an Assistant Treasurer of the Company
setting forth, in reasonable detail, the event requiring the adjustment, the
amount of the adjustment, the method by which such adjustment was calculated
(including a description of the basis on which the Board of Directors of the
Company made any determination hereunder), and shall promptly cause copies of
such certificate to be mailed in the manner provided in Section 17 hereof to the
Holder of this Warrant.
-7-
(b) The adjustment set forth in the certificate furnished pursuant to
Section 3.9(a) shall be final and binding upon the Company and the holders of
the Warrants unless, within 30 days following receipt of such certificate, the
Holders of 20% or more of the outstanding Warrants (determined by the number of
shares of Common Stock represented by each such Warrant if exercised) shall
notify the Company of their disagreement with such adjustments, in which event,
such adjustments shall be determined at the expense of the Company by its
independent auditors (so long as such auditors' accounting firm ranks among the
five largest national accounting firms) or by an independent investment banking
firm or other professional of recognized national standing selected by the
Company and in all such cases (including the Company's selection of its
auditors) reasonably satisfactory to the Required Holders, such determination to
be set forth in a separate report from such auditor, banking firm or other
professional delivered promptly to the Company and each Holder of the Warrants
following the such determination. The Company shall, upon the written request
made at any time by any Holder of the Warrants, furnish to such Holder a
certificate setting forth (i) all adjustments that shall have been made with
respect to the Warrants pursuant to this Section 3, (ii) the per share Warrant
Price at the time in effect and (iii) the number of shares of Common Stock which
at the time would be received upon the exercise of the then outstanding
Warrants.
Section 4. Mergers, Consolidations, Sales, Reorganizations or
Reclassification.
In the case of any consolidation or merger of the Company with another
entity (regardless of whether the Company is a surviving entity), or the sale of
all or substantially all of its assets to another entity, or any reorganization,
recapitalization or reclassification of the Common Stock or other equity
securities of the Company, then, as a condition of such consolidation, merger,
sale, reorganization, recapitalization or reclassification, lawful and adequate
provision shall be made whereby the Holder of this Warrant shall thereafter have
the right to receive upon the basis and upon the terms and conditions specified
herein and in lieu of the shares of Common Stock immediately theretofore
purchasable hereunder, such shares of stock, securities or assets (including,
without limitation, cash) as may (by virtue of such consolidation, merger, sale,
reorganization, recapitalization or reclassification) be issued or payable with
respect to or in exchange for a number of outstanding shares of Common Stock
equal to the number of shares of Common Stock immediately theretofore so
purchasable hereunder had such consolidation, merger, sale, reorganization,
recapitalization or reclassification not taken place, and in any such case,
appropriate provisions shall be made with respect to the rights and interests of
the Holder of this Warrant to the end that the provisions hereof (including,
without limitation, provisions for adjustment of the per share Warrant Price)
shall thereafter be applicable, as nearly as may be, in relation to any shares
of stock, securities or assets thereafter deliverable upon exercise of this
Warrant. The Company shall not effect any such consolidation, merger, sale,
reorganization, recapitalization or reclassification, unless prior to or
simultaneously with the consummation thereof, the successor entity (if other
than the Company) resulting from such consolidation, merger, reorganization,
recapitalization or reclassification or the entity purchasing such assets shall
assume by written instrument executed and mailed or delivered to the Holder of
this Warrant, the obligation to deliver to such Holder such shares of stock,
securities or assets as, in accordance with the foregoing provisions, such
Holder may be entitled to receive.
-8-
Section 5. Dissolution or Liquidation.
In the event of any proposed distribution of the assets of the Company
in dissolution or liquidation except under circumstances when the foregoing
Section 4 shall be applicable, the Company shall mail notice thereof in the
manner provided in Section 17 hereof to the Holder of this Warrant and shall
make no distribution to shareholders until the expiration of 30 days from the
date of mailing of the aforesaid notice and, in any such case, the Holder of
this Warrant may exercise the purchase rights with respect to this Warrant
within 30 days from the date of mailing such notice and all rights herein
granted not so exercised within such 30-day period shall thereafter become null
and void.
Section 6. Notice of Extraordinary Dividends.
If the Board of Directors of the Company shall declare any dividend or
other distribution on its Common Stock except out of earnings or surplus or by
way of a stock dividend payable on its Common Stock, the Company shall mail
notice thereof in the manner provided in Section 17 hereof to the Holder of this
Warrant not less than 30 days prior to the record date fixed for determining
shareholders entitled to participate in such dividend or other distribution and
the Holder of this Warrant shall not participate in such dividend or other
distribution or be entitled to any rights on account or as a result thereof
(except adjustments in the per share Warrant Price as provided in Section 3.5),
unless and to the extent that this Warrant may be exercised pursuant to its
terms and is so exercised prior to such record date. The provisions of this
paragraph shall not apply to distributions made in connection with transactions
covered by Section 4 hereof.
Section 7. Fractional Shares.
Fractional shares shall not be issued upon the exercise of this Warrant,
but in any case where the Holder hereof would, except for the provisions of this
paragraph, be entitled to receive a fractional share upon the complete exercise
of this Warrant, the Company shall, upon the exercise of this Warrant for the
largest number of whole shares then called for, pay to the Holder of this
Warrant a sum in cash equal to the proportional part of the per share Warrant
Price represented by such fractional share.
Section 8. Fully Paid Stock; Taxes.
The Company covenants and agrees that the shares of stock represented by
each and every certificate for its Common Stock to be delivered on the exercise
of the purchase rights and the payment of the applicable purchase price herein
provided for shall, at the time of such delivery, be validly issued and
outstanding and be fully paid and nonassessable. The Company further covenants
and agrees that it will pay when due and payable any and all Federal, State and
local taxes (other than taxes in respect of income) which may be payable in
respect of the delivery of this Warrant or any Common Stock or certificates
therefor upon the exercise of the purchase rights herein provided for pursuant
to the provisions hereof. The Company shall not, however, be required to pay any
tax which may be payable solely in respect of any transfer and
-9-
delivery of stock certificates in a name other than that of the Holder
exercising this Warrant, and any such tax shall be paid by such holder at the
time of presentation.
Section 9. Restrictions on Transferability.
Section 9.1. In General. This Warrant and the Common Stock issued upon
the exercise hereof shall not be transferable except upon the conditions
hereinafter specified, which conditions are intended to insure compliance with
the provisions of the Securities Act (or any similar Federal statute at the time
in effect) and any applicable State securities laws in respect of the transfer
of this Warrant or any such Common Stock.
The Holder of each Warrant or any Restricted Stock, by its acceptance
thereof, agrees to sell or otherwise transfer such Warrant or Restricted Stock,
as the case may be, in compliance with and so as not to result upon consummation
of such sale or transfer in any violation of applicable law.
Section 9.2. Restrictive Legends. Each Warrant shall bear on the face
thereof a legend substantially in the form of the notice endorsed on the first
page of this Warrant.
Each certificate for shares of Common Stock initially issued upon the
exercise of any Warrant and each certificate for shares of Common Stock issued
to a subsequent transferee of such certificate shall, unless otherwise permitted
by the provisions of this Section 9.2, bear on the face thereof a legend reading
substantially as follows:
"The shares evidenced by this Certificate have not
been registered or qualified under the Securities
Act of 1933, as amended, or any state securities
laws and may not be sold or transferred unless
registered or qualified pursuant to such Act and
applicable state securities laws or an exemption
from registration under such Act or such
applicable state securities laws is available, and
are transferable only upon the conditions
specified in the Warrant pursuant to which such
shares were issued."
In the event that a registration statement covering the Underlying Shares
or the Restricted Stock shall become effective under the Securities Act and
under any applicable State securities laws or in the event that the Company
shall receive an opinion of counsel to the Holder of this Warrant (which may be
internal counsel to such Holder) that, in the opinion of such counsel, such
legend is not, or is no longer, necessary or required (including, without
limitation, because of the availability of the exemptions afforded by Rule 144
or Rule 144A of the General Rules and Regulations of the Commission), the
Company shall, or shall instruct its transfer agents and registrars to, remove
such legend from the certificates evidencing the Restricted Stock or issue new
certificates without such legend in lieu thereof. The Company agrees to bear all
expenses in connection with the matters covered by this Section 9.2.
-10-
Section 9.3. Transfers to Competitors. No Holder of a Warrant or any
Restricted Stock may Transfer any Warrant or any Restricted Stock beneficially
owned by such Holder to a Competitor.
Section 9.4. Transfers with Related Securities. No Holder of a Warrant
may transfer a Warrant or any portion thereof unless the Holder concurrently
transfers to the same transferee that number of the shares of Series B Preferred
Stock held by such Holder which represents the same proportion of the Holder's
investment in the Series B Preferred Stock as the Warrant or portion thereof
being transferred represents in its investment in the Warrants immediately prior
to the transfer.
Section 9.5. Minimum Transfers. No Holder of a Warrant may transfer any
Warrant in part in denominations of less than 5% of the aggregate number of all
shares of Common Stock into which all Warrants at the time outstanding are
exercisable (or such lesser amount as shall constitute such Holder's entire
investment in the Warrants).
Section 10. Partial Exercise and Partial Assignment.
Section 10.1. Partial Exercise. If this Warrant is exercised in part only,
the Holder shall surrender this Warrant upon such exercise and shall receive a
new Warrant, registered in the name of the Holder or its nominee and setting
forth a new number of shares in respect of which this Warrant shall not have
been exercised as provided for in Section 1 and a new Aggregate Warrant Price in
the first paragraph of page one hereof, which shall be proportionately adjusted
to reflect such partial exercise.
Section 10.2. Assignment. Subject to Section 9, this Warrant may be
assigned either in whole or in part by surrender of this Warrant at the
principal office of the Company in Irvine, California (with the assignment or,
as the case may be, partial assignment form at the end hereof duly executed). If
this Warrant is being assigned in whole and the Holder hereof previously has not
partially exercised this Warrant, the assignee shall receive a new Warrant
(registered in the name of such assignee or its nominee) which new Warrant shall
cover the number of shares assigned and the Aggregate Warrant Price applicable
to such shares. If this Warrant is being assigned in part and the Holder hereof
previously has not partially exercised this Warrant, the assignor and assignee
shall each receive a new Warrant (which, in the case of the assignee, shall be
registered in the name of the assignee or its nominee), each of which new
Warrants shall cover the number of shares not so assigned and the number of
shares so assigned, respectively, and in each case setting forth the
proportionate Aggregate Warrant Price applicable to such shares. If this Warrant
is being assigned in whole and the holder hereof previously has partially
exercised this Warrant, the assignee shall receive a new Warrant (registered in
the name of such assignee or its nominee), which new Warrant shall cover the
number of shares so assigned and set forth the proportionate Aggregate Warrant
Price applicable to such assigned shares. If this Warrant is being assigned in
part and the Holder hereof previously has partially exercised this Warrant, the
assignor and assignee shall each receive a new Warrant (which, in the case of
the assignee, shall be registered in the name of the assignee or its nominee),
each of which new Warrants shall cover the number of shares not so assigned and
in respect of which no such exercise has been made in the case of the assignor
and the number of shares so assigned in the
-11-
case of the assignee, and in each case setting forth the proportionate Aggregate
Warrant Price applicable to such shares.
Section 11. Reserved.
Section 12. Warrant Denominations.
Warrants are issuable or transferable in the minimum denomination of 10
shares or any integral multiple thereof (as nearly as may be practicable and
subject to required adjustments hereunder), and the Warrants of each
denomination are interchangeable upon surrender thereof at the office of the
Company for Warrants of other denominations (not less than such minimum
denomination, as adjusted), but aggregating the same number of shares as the
Warrants so surrendered. All Warrants will be dated the same date as this
Warrant.
Section 13. Definitions.
In addition to the terms defined elsewhere in this Warrant, the following
terms have the following respective meanings:
The term "Additional Shares of Common Stock" shall mean all shares of
Common Stock issued by the Company after the Closing Date, except:
(a) Common Stock issued upon exercise of the Warrants and the Class B
Warrants and Common Stock issued upon conversion Series B Preferred Stock
at the Conversion Price (as defined in the Board Resolutions creating the
Series B Preferred Stock;
(b) Common Stock issued to officers, directors, employees and members
of the Scientific Advisory Board of the Company and Common Stock issued
pursuant to employee stock option or stock purchase plans approved by the
Board of Directors, provided that the aggregate number of shares of Common
Stock issued and/or issuable to such persons and pursuant to all such plans
and agreements shall not in the aggregate at any time exceed 9,000,000
shares (as such number of shares shall be appropriately adjusted by the
Board of Directors for stock splits, dividends, combinations and other
similar events), it being understood that the shares of Common Stock
excluded pursuant to this clause (b) are in addition to shares excluded
pursuant to clause (d);
(c) Common Stock issued in connection with a corporate collaboration,
development agreement, or commercial relationship which is not primarily
for the purpose of obtaining financing, approved by the Board of Directors
and for consideration equal to or greater than the fair market value of
such shares of Common Stock at the time of issue;
(d) Up to 16,560,176 shares of Common Stock issued upon conversion or
exercise of convertible securities, options and warrants outstanding on
November 24,
-12-
1999 (as such number of shares shall be appropriately adjusted by the Board
of Directors for stock splits, dividends, combinations and other similar
events), which amount includes 25,557,091 shares of Common Stock issuable
upon conversion of the Series A Preferred Stock;
(e) Common Stock issued upon conversion of the Series A Preferred
Stock;
(f) Common Stock valued at up to $10,000,000 issued as consideration
in connection with a single acquisition transaction to be made be the
Company on or before December 31, 2000 involving a medical therapeutics
company consistent with the Company's business plan;
(g) Up to 250,000 shares of Common Stock issued substantially
concurrently with the initial issuance of the Series B Preferred Stock to
holders of the Company's warrants existing at such time and resulting from
the operation of dilution protection provisions in such warrants arising
principally from the issuance of the Warrants; and
(h) Common Stock issued with the affirmative vote or written consent
of the holders of 66-2/3% or more of the then outstanding Warrants
(determined by the number of shares of Common Stock represented by each
such Warrant if exercised).
The term "Adjusted Number of Shares" shall mean, subject to adjustment as
described in Section 3.7, as of the Exercise Date, that number set forth in the
chart below corresponding to the Current Market Price of the Common Stock of the
Company on such date:
-13-
---------------------------------------------------------------------------
If the Current Market Price on the The Adjusted Number of Shares
First Day of the Exercise Period is: Shall be:
---------------------------------------------------------------------------
Less than or equal to $3.00 [Holder's Pro Rated Share of]
6,000,000
---------------------------------------------------------------------------
$3.01 to $3.50 (inclusive) 5,000,000
---------------------------------------------------------------------------
$3.51 to $4.00 (inclusive) 4,000,000
---------------------------------------------------------------------------
$4.01 to $4.50 (inclusive) 3,000,000
---------------------------------------------------------------------------
$4.51 to $5.00 (inclusive) 2,000,000
---------------------------------------------------------------------------
$5.01 or greater 0
---------------------------------------------------------------------------
The term "Aggregate Warrant Price" shall mean, as of the date of any
determination, the amount computed as provided in the first paragraph of this
Warrant.
The term "Business Day" shall mean any day other than a Saturday, Sunday or
other day on which banks in Los Angeles, California or New York, New York are
required by law to close or are customarily closed.
The term "Class B Warrants" shall mean the Class B Warrants to purchase
Common Stock of the Company issued on the Closing Date pursuant to the
Securities Agreement and all other warrants issued in exchange or substitution
therefor.
The term "Closing Date" shall have the meaning ascribed to such term in the
Securities Agreement.
The term "Commission" shall mean the Securities and Exchange Commission, or
any other Federal agency at the time administering the Securities Act.
The term "Common Stock" as used herein shall include (a) the Company's
Common Stock, $0.001 par value, authorized on the Closing Date, and (b) any
other class or series of capital stock of the Company now or hereafter
authorized the right of which to share in distributions either of earnings or
assets of the Company is without limit as to any amount or percentage as and to
the extent no amounts payable on or in respect of such Common Stock and no
rights arising in connection therewith have preference over any other Common
Stock upon dissolution, liquidation or winding up of the Company.
The term "Competitive Business Line" shall mean either (a) the business of
cellular therapy or the development of health care products involving cellular
therapy or (b) the sale, marketing or manufacture of medical devices for use in
the health care industry.
-14-
The term "Competitor" shall mean (a) any Person which is engaged in a
Competitive Business Line or (b) any Person which at the time owns more than
forty percent (40%) of the Voting Stock of such Competitor and in connection
therewith exercises control over management of a Person that is engaged in a
Competitive Business Line, provided in any event that:
(i) the provision of investment advisory services by a Person to a
Plan which is owned or controlled by a Person which would otherwise be a
Competitor shall not in any event cause the Person providing such services
to be deemed to be a Competitor;
(ii) in no event shall an Institutional Holder be deemed a
Competitor unless such Institutional Holder owns or holds more than 50% of
the Voting Stock of, and in connection therewith exercises control over
management of, a Person that is engaged in a Competitive Business Line;
(iii) in no event shall an Institutional Holder be deemed a
Competitor if such Institutional Holder is a pension plan sponsored by a
Person which would otherwise be a Competitor but which is a regular
investor in privately placed Securities and such pension plan has
established procedures which will prevent confidential information supplied
to such pension plan by the Company from being transmitted or otherwise
made available to such plan sponsor; and
(iv) an Institutional Holder that would otherwise be deemed a
Competitor pursuant to the foregoing provisions of this definition by
virtue of its ownership or control as a portfolio investment of the equity
Securities of any Person primarily engaged in a Competitive Business Line,
shall not be deemed a Competitor if such Institutional Holder has
established procedures which will prevent confidential information supplied
to such Institutional Holder by the Company from being transmitted or
otherwise made available to such Person.
The term "Convertible Securities" shall mean evidences of indebtedness,
shares of stock or other securities which are convertible into or exchangeable
for Additional Shares of Common Stock, either immediately or upon the arrival of
a specified date or the happening of a specified event, including, without
limitation, securities of any class or classes which are convertible into shares
of Common Stock and for which the Company exchanges any shares of Series B
Preferred Stock.
The term "Current Market Price" shall mean, at the date of determination
thereof, an amount equal to the Market Price as of the Business Day occurring
most recently prior to such determination (the "Determination Date"). The
"Market Price" as of such Business Day shall be the average of the last reported
sale prices reported on The Nasdaq Stock Market's National Market, as furnished
by NASDAQ (or such other market which is on the date of determination the
principal market by trading volume for the Common Stock) for the immediately
preceding ten trading days ending on (and including) such Business Day, or, if
no sales take place on such days on such system, the average of the closing bid
and asked prices for such days as officially quoted by NASDAQ (or such other
principal market), or, if such price at the time is not available from such
system, the market price for such Business Day shall be the average of the
reported
-15-
closing bid and asked prices for such days in the over-the-counter market, as
furnished by NASDAQ, or, if such price at the time is not available from such
system, such price shall be determined in good faith by the Company's Board of
Directors and concurred in by the Required Holders.
The term "Exercise Date" shall mean the date on which this Warrant is
exercised.
The term "Exercise Period" shall mean the period beginning at 9:00 A.M.
(New York, New York time) on November 24, 2004 and ending at 5:00 P.M. (New
York, New York time) on December 16, 2004 (the "Expiration Date").
The term "Expiration Date" shall mean December 16, 2004.
The term "Holders" shall mean all of the holders of the Warrants or
Restricted Stock issued pursuant thereto and the term "Holder" shall mean any
holder of any Warrant, Underlying Shares or Restricted Stock issued pursuant
thereto.
The term "Initial Exercise Time" shall mean 9:00 a.m. (New York, New York
time) on November 24, 2004.
The term "Institutional Holder" shall mean (a) any original purchaser of
the Warrants, (b) any holder of more than 10% of the Warrants and/or Restricted
Stock, and (c) any bank, trust company, savings and loan association or other
financial institution, any pension plan, any investment company, any insurance
company, any broker or dealer, or any other similar financial institution or
entity, regardless of legal form, provided that for purposes of the definition
of "Competitor," a holder of the type described in clause (b) (and no other
clause) shall not be included in the term "Institution Holder."
The term "Permitted Consideration" shall mean each of the following (or any
combination thereof): (a) cash or other funds immediately available to the
Company; (b) shares of Series B Preferred Stock; and (c) Warrants.
The term "Person" shall mean an individual, partnership, limited liability
company, corporation, trust or unincorporated organization, and a government and
any agency or political subdivision thereof.
The term "Required Holders" shall mean, at the time of any determination,
the Holders of (a) 66-2/3% of the Warrants (determined by the number of shares
of Common Stock represented by each such Warrant as if exercised) and
(b) 66-2/3% of the Restricted Stock.
The term "Restricted Stock" shall mean the shares of Common Stock of the
Company issued upon the exercise of any of the Warrants and evidenced by a
certificate required to bear the legend specified in Section 9.2 hereof.
-16-
The term "Securities Act" shall mean the Securities Act of 1933, or any
similar Federal statute, and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.
The term "Securities Agreement" shall mean the Securities Agreement dated
as of November 24, 1999, between the Company and the institutional investors
which are parties thereto, as amended from time to time.
The term "Series B Preferred Stock" shall mean the Company's Series B
Cumulative Convertible Preferred Stock, $.001 par value, authorized on the
Closing Date.
The term "Transfer" shall mean any sale, transfer, assignment, pledge or
creation of any other encumbrance.
The term "Underlying Shares" shall mean the shares of Common Stock of the
Company issuable upon exercise of any of the Warrants.
The term "Warrants" as used herein shall refer to, collectively, this Class
A Warrant and all other warrants issued in exchange or substitution for this
Class A Warrant.
Section 14. Lost, Stolen Warrants, Etc.
In case this Warrant shall be mutilated, lost, stolen or destroyed, the
Company may issue a new Warrant of like date, tenor and denomination and deliver
the same in exchange and substitution for and upon surrender and cancellation of
the mutilated Warrant, or in lieu of the Warrant lost, stolen or destroyed, upon
receipt of evidence satisfactory to the Company of the loss, theft or
destruction of such Warrant, and upon receipt of indemnity satisfactory to the
Company. If the original Holder of this Warrant or any subsequent Institutional
Holder is the owner of this Warrant at the time of it shall be lost, stolen or
destroyed, then the affidavit of an authorized officer of such owner, setting
forth the fact of such loss, theft or destruction and of its ownership of this
Warrant at the time of such loss, theft or destruction shall be accepted as
satisfactory evidence thereof and no further indemnity shall be required as a
condition to the execution and delivery of a new Warrant other than the written
agreement of such owner to indemnify the Company.
Section 15. Warrant Holder Not Shareholder.
Except as provided in Section 22 and as otherwise provided by law, this
Warrant does not confer upon the Holder hereof any right to vote or to consent
or to receive notice as a shareholder of the Company, as such, in respect of any
matters whatsoever, or any other rights or liabilities as a shareholder, prior
to the exercise hereof as hereinbefore provided.
-17-
Section 16. Exercise of Remedies.
In the event that the Company shall fail to observe any provision contained
in this Warrant, the Holder hereof and/or any Holder of Common Stock issued
hereunder, as the case may be, may enforce its rights hereunder by suit in
equity, by action at law, or by any other appropriate proceedings in aid of the
exercise of any power granted in this Warrant and, without limiting the
foregoing, said Holder shall be entitled to the entry of a decree for specific
performance and to such other and further relief as such court may decree.
Section 17. Notices.
All communications provided for hereunder shall be in writing and, if to
the Holder of this Warrant or any Common Stock issued hereunder, delivered or
mailed prepaid by registered or certified mail or overnight air courier, or by
facsimile communication, in each case addressed to the address of such Holder
appearing on Schedule I to the Securities Agreement (in the case of the initial
Holder of this Warrant) or such other address as such Holder or any subsequent
Holder of this Warrant or any such Common Stock may designate to the Company in
writing, and if to the Company, delivered or mailed by registered or certified
mail or overnight air courier, or by facsimile communication, addressed to the
Company at:
Nexell Therapeutics Inc.
0 Xxxxxx
Xxxxxx, Xxxxxxxxxx 00000
Attention: President,
Telecopy No.: 000-000-0000
or to such other address as the Company may in writing designate to any such
Holder; provided that a notice to the initial Holder of this Warrant or any
Common Stock issued hereunder by overnight air courier shall only be effective
if delivered to said initial Holder at a street address designated for such
purpose in said Schedule I, and a notice to any Holder of this Warrant or any
Common Stock issued hereunder by facsimile communication shall only be effective
if confirmed by transmission of a copy thereof by prepaid overnight air courier.
Section 18. Severability.
Should any part of this Warrant for any reason be declared invalid, such
decision shall not affect the validity of any remaining portion, which remaining
portion shall remain in force and effect as if this Warrant had been executed
with the invalid portion thereof eliminated, and it is hereby declared the
intention of the parties hereto that they would have executed and accepted the
remaining portion of this Warrant without including therein any such part, parts
or portion which may, for any reason, be hereafter declared invalid.
-18-
Section 19. Register; Closing of Transfer Books.
The Company agrees to maintain at its principal offices books for the
registration and transfer of the Warrants. The right to exercise this Warrant
shall not be suspended during any period that the stock transfer books of the
Company for its Common Stock may be closed. The Company shall not be required,
however, to deliver certificates of its Common Stock upon such exercise while
such books are duly closed for any purpose, but the Company may postpone the
delivery of the certificates for such Common Stock until the opening of such
books, and they shall, in such case, be delivered forthwith upon the opening
thereof, or as soon as practicable thereafter.
Section 20. Financial Statements; Notice of Exercise Period.
(a) The Company covenants and agrees that Section 4.01 of the Securities
Agreement is incorporated by reference mutatis mutandis with the same force and
effect as if such covenant were set forth in full herein, whether or not the
Preferred Stock of the Company issued pursuant to the Securities Agreement are
converted in full and the Securities Agreement thereby discharged and
terminated, with the effect and result that the Company will deliver each and
all of the financial statements, reports, notices and other information referred
to in said Section 4.01 as and to the extent therein provided, provided that if
the Holder of this Warrant shall at any time so request, the Company shall cease
its delivery of the information referred to in said Section 4.01 until such time
as the Holder shall again require delivery.
(b) Between August 1, 2004 and September 1, 2004, the Company agrees to
give each Holder of the Warrants written notice of the initiation of the
Exercise Period, referencing the Warrants and specifying the date on which the
Exercise Period begins and the date on which the Exercise Period ends. If the
Company fails to provide such written notice to a Holder during the time period
specified, then the Exercise Period hereunder shall be extended to a date which
is 15 business days following the date upon which such Holder does in fact
receive such written notice (or such later date as may be the Expiration Date
originally provided for under this Warrant).
Section 21. [Intentionally Omitted].
Section 22. Restrictions on Capital Structure.
The Company will not, without the written consent of the Required Holders,
take any action which:
(a) materially restricts the right or ability of the Company to
perform its obligations under the Warrants; or
(b) amends or changes its certificate of incorporation or bylaws
(each as currently amended and/or restated) if such amendment or change
would materially limit or prohibit the Company from complying with the
terms of the Warrants or would otherwise materially and adversely affect
the rights of the Holders under the Warrants.
-19-
Section 23. Successors and Assigns.
This Agreement shall be binding upon each of Company and the Holder of this
Warrant and each of their respective successors and permitted assigns.
Notwithstanding the foregoing, the Company may not assign any of its rights or
obligations hereunder without the prior written consent of the Holder.
Section 24. Index and Captions.
The index and the descriptive headings of the various sections of this
Warrant are for convenience only and shall not affect the meaning or
construction of the provisions hereof.
Section 25. Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.
This Warrant, including the construction, validity and performance hereof
and the obligations arising hereunder, and all amendments and supplements hereof
and all waivers and consents hereunder, shall be construed in accordance with
and governed by the laws of the State of New York without giving effect to any
choice of law or conflicts of law provision or rule that would cause the
application of the laws of any other jurisdiction. Any legal action or
proceeding with respect to this Warrant or any document related hereto shall be
brought in the courts of the State of New York sitting in the County of New York
or of the United States of America for the State of New York sitting in the
County of New York or the courts of the State of Illinois sitting in the County
of Xxxx or of the United States of America for the State of Illinois sitting in
the Northern District of Illinois, and, by execution and delivery and/or
acceptance of this Warrant, the Company and the Holder of this Warrant each
hereby accepts the non-exclusive jurisdiction of the aforesaid courts.
In addition, the Company hereby irrevocably and unconditionally waives any
objection which it may now or hereafter have to the laying of venue of any of
the aforesaid actions, suits or proceedings arising out of or in connection with
this Warrant or any document related hereto brought in any of the aforesaid
courts, and hereby further irrevocably and unconditionally waives and agrees not
to plead or claim that any such action, suit or proceeding brought in any such
court has been brought in an inconvenient forum.
The Company and the Holder of this Warrant each hereby irrevocably waives
all right to a trial by jury in any suit, action or other proceeding instituted
by or against it in respect of its obligations hereunder or the transactions
contemplated hereby.
-20-
In Witness Whereof, Nexell Therapeutics Inc. has caused this Warrant to be
signed by its _______________________ and to be dated this ___ day of November,
1999.
Nexell Therapeutics Inc.
By /s/
_______________________________
Name: ___________________________
Title: __________________________
-21-
Form of Notice of Exercise Period
[Date]
[August 1, 2004 - September 1, 2004]
To the Holders of the
Class A Warrants Listed
On the Attached Schedule
Re: Exercise Period of Class A Warrants
of
Nexell Therapeutics Inc.
Ladies and Gentlemen:
Reference is hereby made to that certain Securities Agreement dated as of
November 24, 1999 pursuant to which the following securities were issued and
sold to the Purchasers named therein: (a) the Series B Cumulative Convertible
Preferred Stock of Nexell Therapeutics Inc. (the "Company"), (b) the Put Right
Certificates issued by Xxxxxx International Inc. entitling the holders thereof
to require Xxxxxx International Inc. to purchase the Series B Preferred Stock on
or before November 24, 2004, (c) the Class A Warrants of the Company entitling
the holders thereof to purchase Common Stock of the Company during the exercise
period specified below and (d) the Class B Warrants of the Company entitling the
holders thereof to purchase Common Stock of the Company on or before
December 16, 2004.
As required by Section 20(b) of the Class A Warrants, the Company hereby
notifies you that the exercise period of the Class A Warrants begins on
November 24, 2004 and ends on December 16, 2004.
Nexell Therapeutics Inc.
By: __________________________
Name:_________________________
Title:________________________
Exhibit A
(to Class A Warrant)
Subscription
Nexell Therapeutics Inc.
The undersigned, _________________________________, pursuant to the
provisions of the within Warrant, hereby elects to purchase _____ shares of
Common Stock pursuant to the attached Warrant.
Signature
Address
Dated:
Assignment
For Value Received _______________________ hereby sells, assigns and
transfers unto ___________________ the within Warrant and all rights evidenced
thereby and does irrevocably constitute and appoint ___________________,
attorney, to transfer the said Warrant on the books of Nexell Therapeutics Inc.
Signature
Address
Dated:
Partial Assignment
For Value Received ___________________ hereby sells, assigns and transfers
unto _______________ that portion of the within Warrant and the rights evidenced
thereby which will on the date hereof entitle the Holder to purchase ______
shares of Common Stock of Nexell Therapeutics Inc. and irrevocably constitutes
and appoints __________________, attorney, to transfer that part of the said
Warrant on the books of said Company.
Signature
Address
Dated:
